{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:35Z","timestamp":1781254595223,"version":"3.54.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:24:44Z","timestamp":1771460684000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions"],"prefix":"10.1016","volume":"26","author":[{"given":"Seda S.","family":"Tolu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.02.007_bib0001","first-page":"1229","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0002","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0003","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0004","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0005","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0006","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0007","series-title":"Outcomes of Relapsed\/Refractory Peripheral T-cell Lymphoma in the Modern Era: Impact of Stem Cell Transplant and Novel Agents","author":"Tolu","year":"2025"},{"issue":"21","key":"10.1016\/j.clml.2026.02.007_bib0008","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"de Leval","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0009","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0010","first-page":"213","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001315","article-title":"Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype","author":"Basha","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2026.02.007_bib0012","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"5","key":"10.1016\/j.clml.2026.02.007_bib0013","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","article-title":"Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with","volume":"33","author":"Huang","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2026.02.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.clml.2026.02.007_bib0015","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2016-07-726455","article-title":"New mutations for nodal lymphomas of TFH origin","volume":"128","author":"Fern\u00e1ndez-Piqueras","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0016","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0017","first-page":"3402","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0018","first-page":"2915","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0019","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2020.262659","article-title":"CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)","volume":"106","author":"Maura","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0020","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1182\/bloodadvances.2023009953","article-title":"TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.02.007_bib0021","first-page":"1278","article-title":"DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS","volume":"140","author":"Herek","year":"2022","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0022","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0023","first-page":"5496","article-title":"ALK\u2212 anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified","volume":"111","author":"Savage","year":"2008","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0024","article-title":"ALK+ lymphoma: clinico-pathological findings and outcome","author":"Falini","year":"1999","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clml.2026.02.007_bib0026","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm1249","article-title":"Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target","volume":"11","author":"Chiarle","year":"2005","journal-title":"Nat med"},{"key":"10.1016\/j.clml.2026.02.007_bib0027","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3324\/haematol.2022.281442","article-title":"ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study","volume":"108","author":"Sibon","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0028","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3324\/haematol.2022.282025","article-title":"DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome","volume":"108","author":"Savage","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.02.007_bib0029","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0030","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","author":"Pedersen","year":"2017","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0031","first-page":"700","article-title":"\u201cDouble-hit\u201d of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative","volume":"135","author":"Karube","year":"2020","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis","author":"AbouYabis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0033","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the german High-grade Non","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0034","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0035","doi-asserted-by":"crossref","first-page":"E562","DOI":"10.3324\/haematol.2018.213512","article-title":"ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0036","first-page":"1009","article-title":"Impact of etoposide and ASCT on survival among patients aged < 65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0037","doi-asserted-by":"crossref","unstructured":"Reimer, P, R\u00fcdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. 2009;27:106\u2013113.","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"10.1016\/j.clml.2026.02.007_bib0038","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0039","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","article-title":"A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission","volume":"13","author":"Mehta","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.02.007_bib0041","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.02.007_bib0042","doi-asserted-by":"crossref","unstructured":"Pasqualucci, L, Wasik, M, Teicher, B & Flenghi, L. Antitumor activity of anti-CD30 immunotoxin (Ber-H2\/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+. https:\/\/ashpublications.org\/blood\/article-abstract\/85\/8\/2139\/123235 (1995).","DOI":"10.1182\/blood.V85.8.2139.bloodjournal8582139"},{"key":"10.1016\/j.clml.2026.02.007_bib0043","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0140-6736(92)91135-U","article-title":"Response of refractory Hodgkin\u2019s disease to monoclonal anti-CD30 immunotoxin","volume":"339","author":"Falini","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.02.007_bib0044","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1046\/j.1365-2141.1995.404942.x","article-title":"Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display","volume":"92","author":"Terenzi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0045","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0046","first-page":"2120","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.02.007_bib0048","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0049","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0050","first-page":"5827","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0051","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0052","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01780-1","article-title":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated peripheral T-Cell lymphoma: results of the PTCL13 phase ib\/II","author":"Chiappella","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0054","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s43018-023-00696-8","article-title":"Lessons from withdrawn accelerated approvals in oncology","volume":"5","author":"Mellgard","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2026.02.007_bib0055","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.007_bib0056","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0057","doi-asserted-by":"crossref","first-page":"3123.1","DOI":"10.1182\/blood-2024-197991","article-title":"Trial in progress: a phase 3, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-Cop to the to the CHOP regimen alone in newly diagnosed patients with peripheral T- cell lymphoma - crescendo","volume":"144","author":"Tiger","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0058","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428194.2024.2329996","article-title":"Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell","volume":"65","author":"Ryu Tiger","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.02.007_bib0059","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","author":"Lemonnier","year":"2018","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0060","first-page":"2194","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0061","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.02.007_bib0062","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus Lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0063","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0064","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and \u03b2-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T","volume":"92","author":"Rodr\u00edguez","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0065","unstructured":"Horwitz S, Ansell S, AI WZ. et al. NCCN Guidelines Version 2.2025 T-Cell Lymphomas. https:\/\/www.nccn.org\/home\/member- (2025)."},{"key":"10.1016\/j.clml.2026.02.007_bib0066","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0067","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70096_766","article-title":"Outcomes of patients with peripheral T-cell lymphoma by race\/ethnicity and clinical trial enrollment","volume":"43","author":"Sanjurjo","year":"2025","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0068","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0069","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.02.007_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41571-024-00972-1","article-title":"Getting the right combination to break the epigenetic code","volume":"22","author":"Tolu","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0071","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0072","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-18-3989","article-title":"Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas","volume":"25","author":"Lue","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.02.007_bib0073","unstructured":"Azacitidine combined with chidamide in the Treatment of newly diagnosed PTCL unfit for conventional chemotherapy ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04480125."},{"key":"10.1016\/j.clml.2026.02.007_bib0074","unstructured":"Prospective, single arm, single center study of duvelisib combined with chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma (PTCL) ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05976997."},{"key":"10.1016\/j.clml.2026.02.007_bib0075","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0076","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.02.007_bib0077","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0078","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0079","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41401-020-00500-8","article-title":"Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clml.2026.02.007_bib0081","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971392.38916.42","article-title":"P1124: duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial expansion phase: outcomes by baseline histology","author":"Mehta-Shah","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.clml.2026.02.007_bib0082","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.02.007_bib0083","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.02.007_bib0084","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0086","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.leukres.2013.12.027","article-title":"Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma","volume":"38","author":"Hamedani","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.02.007_bib0087","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Group study","volume":"35","author":"Moss\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0088","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children\u2019s oncology group trial ANHL12P1","volume":"41","author":"Lowe","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0089","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2026.02.007_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.10017","article-title":"Brigatinib monotherapy in children with R\/R ALK+ ALCL, IMT, or other solid tumors: results from the BrigaPED (ITCC-098) phase 1 study","volume":"42","author":"Rigaud","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.02.007_bib0091","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S1470-2045(21)00536-2","article-title":"Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion","volume":"22","author":"Fischer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0092","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD1-inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.02.007_bib0093","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971464.68430.62","article-title":"P1142: AFM13 in patients with R\/R peripheral T cell lymphoma (PTCL): a post-hoc subgroup analysis from the redirect study","author":"Kim","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.02.007_bib0094","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: the COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9\u2013engineered CAR T cells in patients with","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.02.007_bib0095","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.02.007_bib0096","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.02.007_bib0097","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"14","key":"10.1016\/j.clml.2026.02.007_bib0098","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1007\/s00432-023-05148-5","article-title":"Chimeric antigen receptor T cells march into T cell malignancies","volume":"149","author":"Tang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0100","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0101","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41375-025-02563-0","article-title":"Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes","volume":"39","author":"Suehara","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0102","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","article-title":"Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL","volume":"36","author":"Kameda","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0103","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2024-206606","article-title":"Subsequent treatment and clinical outcome following induction therapy on a phase II study of oral azacitidine plus CHOP for peripheral T-cell lymphoma (PTCL)","volume":"144","author":"Ruan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0104","doi-asserted-by":"crossref","first-page":"TPS7593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7593","article-title":"Alliance A059102: a randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas","volume":"40","author":"Mehta-Shah","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0105","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","author":"Lemonnier","year":"2012","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0106","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","author":"Mckinney","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2026.02.007_bib0107","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","author":"Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2026.02.007_bib0108","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat genet"},{"key":"10.1016\/j.clml.2026.02.007_bib0109","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.02.007_bib0110","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.02.007_bib0111","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000644","article-title":"A survey of somatic mutations in 41 genes in a cohort of T-cell lymphomas identifies frequent mutations in genes involved in epigenetic modification","author":"Fernandez-Pol","year":"2019","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.clml.2026.02.007_bib0112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492835","article-title":"Frequent mutations in natural killer\/T cell lymphoma","volume":"49","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clml.2026.02.007_bib0113","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.02.007_bib0114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14204972","article-title":"Genetics abnormalities with clinical impact in primary cutaneous lymphomas","author":"Gallardo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.02.007_bib0115","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2026.02.007_bib0116","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V122.21.4265.4265","article-title":"EZH2 inhibitor DZNep induces apoptosis in adult T-cell leukemia\/lymphoma cells by BCL2 suppression via regulation of Mir-181a","volume":"122","author":"Daisuke","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.02.007_bib0117","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2026.02.007_bib0118","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12602","article-title":"Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations","volume":"7","author":"Roberti","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.02.007_bib0119","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.02.007_bib0120","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral azacytidine in patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: final analysis of the oracle phase III study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0121","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S2152-2650(23)01392-7","article-title":"TCL-275 updated results of an investigator-initiated phase II study of pembrolizumab and romidepsin for patients with relapsed or refractory T-cell","author":"Iyer","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.02.007_bib0122","first-page":"2161","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.02.007_bib0123","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.02.007_bib0124","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","author":"Tan","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:07:00Z","timestamp":1781251620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000431"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}